Phase I Trial of VS-6766 Alone and in Combination With Everolimus
brief summary
This study is a multi-centre, investigator-initiated, Phase I clinical trial evaluating different dosing schedules of VS-6766, given either alone or in combination with everolimus, in patients with advanced solid tumours or multiple myeloma. The study will investigate whether combining VS-6766 with everolimus can improve the treatment's effectiveness by blocking two important pathways that help cancer cells grow and survive. By targeting both pathways, researchers hope to reduce the likelihood of the cancer becoming resistant to treatment. In Part I of the study, participants will receive VS-6766 on different intermittent dosing schedules to identify the safest and most effective way to administer the drug. The treatment will be given by mouth either two or three times per week in four-week treatment cycles. If significant side effects are observed, the dose may be reduced. The dosing schedule identified as optimal in Part I will be taken forward into Part II. This phase will enrol patients whose cancers have specific genetic changes in the RAS/RAF/MEK pathway, including KRAS, NRAS, or BRAF mutations. Participants will receive either VS-6766 alone or VS-6766 in combination with everolimus. The study will assess the safety and tolerability of the treatment, how the body processes the drugs, and whether the treatment shows signs of benefiting patients. Particular focus will be placed on cancers driven by RAS/RAF pathway mutations, including KRAS-mutant lung cancer.
detailed description
This is a two centre Phase I trial evaluating two intermittent dosing schedules of VS-6766 alone and then in combination with everolimus.
Part I (COMPLETED): Patients will be given VS-6766 (4mg) twice weekly or three times per week in treatment cycles of 4 weeks to investigate a safe and tolerable dose of the drug. Up to six patients will be enrolled to each dosing schedule and once they have completed 1 cycle of treatment the Safety Review Committee (SRC) will review their safety data, PK and PD data and define the optimal schedule to be taken forward into Part II.
On the basis of the previous Phase I trial, dose limiting toxicities (DLTs) are not expected at a dose of 4 mg but in the event of ≥ 2 DLT's occurring in (a) the 2 x weekly arm, then no further patients will recruited into that arm and the schedule will not be taken forward to Part II, or (b) the 3 x weekly arm, a single dose reduction to 3.2mg on the same dosing schedule will be implemented and 6 patients enrolled at the reduced dose. If 4 mg given 3 x weekly is considered non-tolerable, then the SRC may decide to enrol patients to the 3.2 mg dose level in the absence of dose limiting toxicity.
* If both the 2 x weekly (Mon \& Thurs / Tues \& Fri) and 3 x weekly (Mon, Wed \& Fri) schedule are tolerated at 4 mg i.e. \< 2 DLT's out of a 6 patients in each schedule, then the 3 x weekly schedule will be selected. * If the 3 x weekly schedule requires a dose reduction to 3.2 mg and the 2 x weekly schedule is tolerated at 4 mg, then PD data will be evaluated relative to AUC to aid the selection. * If ≥2 DLT's occur out of 6 patients in both schedules (despite the 3 x weekly arm being dose reduced), Part II will not be initiated and the study will be terminated.
Selection of the optimum schedule from Part I will be made by the Safety Review Committee and will be the schedule that delivers the highest, tolerable, cumulative weekly dose.
Part II: Once the optimal dosing schedule has been established in Part I, the following groups of patients will be enrolled:
Part IIA (COMPLETED) - 20 patients with documented RAS-RAF-MEK pathway mutant solid tumours (including KRAS, NRAS or BRAF).
Part IIB (CLOSED) - 10 patients with documented KRAS, NRAS or BRAF multiple myeloma.
NB: In order to accommodate steroid use for patients with multiple myeloma, the optimal dosing schedule as determined in Part I will be administered for 3 weeks followed by a week interruption.
official title
A Phase I Trial of VS-6766 (RO5126766) (a Dual RAF/MEK Inhibitor) Exploring Intermittent, Oral Dosing Regimens in Patients With Solid Tumours or Multiple Myeloma, With an Expansion to Explore Intermittent Dosing in Combination With Everolimus